Last updated on June 2019

An Investigational Immuno-therapy Study to Assess the Safety Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors


Brief description of study

The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery.

The following tumor types are included in this study:

Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy.

Clinical Study Identifier: NCT01968109

Find a site near you

Start Over

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Providence Portland Med Ctr

Portland, OR United States
  Connect »

UPMC Eye and Ear Institute

Pittsburgh, PA United States
  Connect »

Local Institution

Copenhagen, Denmark
  Connect »

Local Institution

Toulouse Cedex 9, France
  Connect »

Local Institution

Marseille Cedex 5, France
  Connect »

Local Institution

Pierre Benite Cedex, France
  Connect »

Md Anderson Can Cnt

Houston, TX United States
  Connect »

Local Institution

Nantes Cedex 01, France
  Connect »

Christie Hospital

Manchester, United Kingdom
  Connect »

Local Institution

Lausanne, Switzerland
  Connect »

University Of Colorado

Aurora, CO United States
  Connect »

Local Institution

Zurich, Switzerland
  Connect »

Mayo Clinic - PPDS

Rochester, MN United States
  Connect »

UCSD Moores Cancer Center

La Jolla, CA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.